Status:
NOT_YET_RECRUITING
A Multicenter, Prospective Study for Glioblastoma Patients
Lead Sponsor:
Larissa University Hospital
Collaborating Sponsors:
University of Thessaly
University of California, San Francisco
Conditions:
Glioblastoma
Eligibility:
All Genders
18+ years
Brief Summary
Glioblastoma (GBM) is the most common and aggressive primary tumor of the adult central nervous system (CNS), with a poor prognosis and median overall survival ranging between 14 to 20 months despite ...
Detailed Description
Brief Background: Glioblastoma remains the most prevalent and aggressive primary tumor of the Central Nervous system (CNS) in adults, with dismal prognosis and median overall survival between 14 to 20...
Eligibility Criteria
Inclusion
- Inclusion criteria:
- Adult patients (\>18 years of age) with
- Glioblastoma based on radiographic features,
- Patients that consent for study participation.
- Exclusion criteria:
- Non adult patients,
- Patients that do not consent for participation in this study,
- Patients with other CNS tumors
Exclusion
Key Trial Info
Start Date :
September 1 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2030
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT07162324
Start Date
September 1 2025
End Date
December 31 2030
Last Update
September 9 2025
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
UCSF Weil Institute for Neurosciences
San Francisco, California, United States, 94143
2
University Hospital of Larissa
Larissa, Thessaly, Greece, 41100
3
Inselspital University Hospital of Bern
Bern, Switzerland, 3010